However, loss of CDX2 expression was weakly correlated with advanced cancer stage (Table S2), and by analyzing the four stages separately, a significant association with a worse 5‐year overall survival was found only in stage IV [HR 3.96; 95% CI 2.50–6.28; P = 3.1 × 10−10, n = 164; formal test for interaction (full multivariable model, stages I–III versus stage IV: P = 0.024; Figs 2C and S2BC)] and confirmed in multivariable analysis restricted to stage IV [HR 2.38; 95% CI 1.26–4.48; P = 0.0074; Table 1 (lower panel)]. This evidence concerns the gene CDX2 and cancer.